Oslo, Norway, 18 August 2022

Nordic Nanovector ASA (OSE: NANOV) ("Nordic Nanovector" or the "Company") today
announces that its Board of Directors (the "Board") has appointed Carnegie
Investment Bank ("Carnegie") to explore strategic options available to the
Company.

The Board has initiated this review aiming to optimise shareholder value
following its recent decision to discontinue the PARADIGME study for Nordic
Nanovector's lead asset Betalutin® and implement a restructuring of the Company.

Chairman, Jan H. Egberts commented: "The decision to discontinue the PARADIGME
study was extremely disappointing. As a result, we are now focused on achieving
an outcome for the Company that creates maximum value for shareholders. We
believe this should include exploring all strategic options and, as a leading
financial advisor in the Nordic region, Carnegie is strongly positioned to help
us achieve the best possible outcome for our shareholders and other
stakeholders."

No assurances can be given as to the outcome or timing of the review process.
Nordic Nanovector does not intend to make any further public comment regarding
the review until it has been completed or the Company determines that disclosure
is required or appropriate.

Advokatfirmaet Selmer AS is acting as Nordic Nanovector's legal advisor.

For further information, please contact:

IR enquiries

Jan H. Egberts, Chairman of Nordic Nanovector
Tel: +31 614672518
Email: janegberts@aol.com

Media Enquiries

Mark Swallow/Frazer Hall (MEDiSTRAVA Consulting)
Tel: +44 203 928 6900
Email: nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in radionuclide therapy of cancer. In
addition to Betalutin[®],[ ]for which Nordic Nanovector retains global marketing
rights, the Company's novel pipeline includes Humalutin[®], a radioimmunotherapy
candidate based on a chimeric anti-CD37 antibody and the beta emitter lutetium
-177 for NHL